Depression Therapy to Improve Cardiovascular Risk in HIV

Completed · Not applicable

Conditions studied: Depression, HIV

In brief

This trial will determine if depression treatment will reduce cardiovascular risk in HIV-infected patients already receiving HIV treatments. Half of the participants will undergo a specific computerized depression treatment with the other half receiving usual care from their HIV providers.

Key facts

Study ID

NCT02309372

Run by

Indiana University

People needed

54

Starts

2015-04-01

Expected to finish

2019-04-01

Last updated by the study team

2020-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 infection, documented by both: (1) any licensed rapid HIV test or HIV enzyme test kit at any time prior to study entry and (2) by at least one detectable HIV-1 antigen or at least one detectable plasma HIV-1 RNA viral load
• Age equal to or greater than 18 years
• Receipt of antiretroviral therapy of any kind for at least 360 days prior to screening
• Note: Interruptions in ART of up to 14 days total during the 360 days prior to screening are allowed
• HIV-1 RNA level < 75 copies/mL at screening
• NOTE: There are no CD4 cell count eligibility criteria for this trial
• For women who are still of reproductive potential, a negative urine pregnancy test
• Depression as defined by having a score ≥ 10 on the PHQ-9 questionnaire

You may not qualify if…

• Inability to complete written, informed consent
• Incarceration at the time of any study visit
• Active suicidality, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions on the Patient Suicidality Form (with last suicide attempt within the past ten years)
• Diagnosed vascular disease (documented history of angina pectoris, coronary disease, peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known atherosclerotic disease)
• History of congestive heart failure, even if currently compensated
• Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosis, inflammatory bowel diseases, other collagen vascular diseases)
• Note: Hepatitis B or C co-infections are NOT exclusionary
• Known or suspected malignancy requiring systemic treatment within 180 days of screening
• NOTE: Localized treatment for skin cancers is not exclusionary
• History of Raynaud's phenomenon
• History of cardiac arrhythmias or cardiomyopathy
• Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the local reference range on most recent clinical assessment
• History of carotid bruits
• Systolic blood pressure > 160 mmHg or diastolic blood pressure > 110 mmHg at screening
• Screening estimated glomerular filtration rate (eGFR) < 50 mL/min/1.732 (using the 2009 CKD-EPI equation) using a serum creatinine level measured at screening
• Screening glucose ≥ 140 mg/dL or hemoglobin A1c > 8.0%
• Screening total cholesterol > 240 mg/dL
• Therapy for serious medical illnesses within 14 days prior to screening
• Note: Therapy for serious medical illnesses that overlaps with a main study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation
• Pregnancy or breastfeeding during the course of the study
• Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids (of any dose), or anabolic steroids at screening
• Note: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors
• Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
• History of schizophrenia or bipolar disorder

Where it is running

• Indiana University Health University Hospital, Indiana Clinical Research Center — Indianapolis, Indiana, United States
• Infectious Diseases Research Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.